Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | NOS3 | P29474 | 2/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.43 |
| ▸ | NOS2 | P35228 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1053125 | 0.89 | MGLL (0.53) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL2747979 | 0.89 | MGLL (0.53) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL4941753 | 0.87 | MGLL (0.50) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL7310199 | 0.87 | MGLL (0.50) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL10201893 | 0.86 | MGLL (0.49) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL16284648 | 0.84 | ALDH1A1 (0.67) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL22137002 | 0.84 | ALDH1A1 (0.67) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL26226843 | 0.84 | ALDH1A1 (0.67) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL10201890 | 0.84 | MGLL (0.55) | MGLLALDH1A1MAPTNPC1RAB9A | |
| SCHEMBL7174053 | 0.83 | MGLL (0.57) | MGLLALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050131042-A1 | HIV protease inhibiting compounds | ABBOTT LABORATORIES | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050131042-A1 | HIV protease inhibiting compounds | SERPINB1, HPN, DNPEP | MGLL 850/4885ALDH1A1 2920/4885MAPT 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.